The estimated Net Worth of Geoffrey Crouse is at least $810 Thousand dollars as of 22 February 2021. Mr. Crouse owns over 10,000 units of Invitae Corp stock worth over $385 and over the last 9 years he sold NVTA stock worth over $614,600. In addition, he makes $195,180 as Independent Director at Invitae Corp.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Crouse NVTA stock SEC Form 4 insiders trading
Geoffrey has made over 3 trades of the Invitae Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 10,000 units of NVTA stock worth $486,200 on 22 February 2021.
The largest trade he's ever made was buying 15,000 units of Invitae Corp stock on 18 November 2016 worth over $93,750. On average, Geoffrey trades about 2,000 units every 104 days since 2015. As of 22 February 2021 he still owns at least 19,259 units of Invitae Corp stock.
You can see the complete history of Mr. Crouse stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Geoffrey Crouse biography
Geoffrey S. Crouse serves as Independent Director of the Company. Mr. Crouse has served as Chief Executive Officer of Syneron Candela, a privately held non-surgical aesthetic device company. From December 2015 to July 2017, Mr. Crouse was a consultant for private equity evaluating investment opportunities. Mr. Crouse served as Chief Executive Officer of Cord Blood Registry from September 2012 to August 2015 when it was sold to AMAG Pharmaceuticals. He served as Executive Vice President of AMAG until December 2015. Cord Blood Registry stores stem cells from umbilical blood and tissues. From April 2011 through September 2012, Mr. Crouse was a consultant for private equity evaluating investment opportunities. He previously served as Chief Operating Officer at Immucor, Inc., an in vitro diagnostics company, from August 2009 to April 2011. Prior to Immucor, he served as Vice President of the life sciences business at Millipore
What is the salary of Geoffrey Crouse?
As the Independent Director of Invitae Corp, the total compensation of Geoffrey Crouse at Invitae Corp is $195,180. There are 7 executives at Invitae Corp getting paid more, with Sean George having the highest compensation of $5,319,510.
How old is Geoffrey Crouse?
Geoffrey Crouse is 49, he's been the Independent Director of Invitae Corp since 2012. There are 10 older and 7 younger executives at Invitae Corp. The oldest executive at Invitae Corp is Dr. Robert L. Nussbaum, 71, who is the Chief Medical Officer.
What's Geoffrey Crouse's mailing address?
Geoffrey's mailing address filed with the SEC is C/O INVITAE CORPORATION, 1400 16TH STREET, SAN FRANCISCO, CA, 94103.
Insiders trading at Invitae Corp
Over the last 10 years, insiders at Invitae Corp have traded over $68,349,838 worth of Invitae Corp stock and bought 2,982,686 units worth $18,086,236 . The most active insiders traders include Bros. Advisors Lp Baker Bro..., Bros. Advisors Lpbaker Feli..., and James E Deerfield Mgmt L.P..... On average, Invitae Corp executives and independent directors trade stock every 14 days with the average trade being worth of $540. The most recent stock trade was executed by Robert L Nussbaum on 13 June 2023, trading 7,086 units of NVTA stock currently worth $9,779.
What does Invitae Corp do?
invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people. specializing in genetic diagnostics for hereditary disorders, invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today. choose from our curated panels or design your own test for the same low price. today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. together we can improve healthcare for billions of people.
What does Invitae Corp's logo look like?
Complete history of Mr. Crouse stock trades at AMAG Pharmaceuticals and Invitae Corp
Invitae Corp executives and stock owners
Invitae Corp executives and other stock owners filed with the SEC include:
-
Sean George,
Chairman of the Board, President, Chief Executive Officer, Co-Founder -
Shelly Guyer,
Chief Financial Officer -
Katherine Stueland,
Chief Commercial Officer -
Robert Nussbaum,
Chief Medical Officer -
Shelly D. Guyer,
Chief Financial Officer -
Dr. Sean Emerson George Ph.D.,
Co-Founder, Pres, CEO & Director -
Lee Bendekgey,
Chief Policy Officer -
Geoffrey Crouse,
Independent Director -
Eric Aguiar,
Independent Director -
Christine Gorjanc,
Lead Independent Director -
Chitra Nayak,
Independent Director -
Jason Myers,
Director -
Kimber Lockhart,
Director -
Karthik Suri,
Chief Digital Officer -
Thomas Brida,
General Counsel, Secretary -
Robert Werner,
Chief Accounting Officer -
Kenneth Knight,
Chief Operating Officer -
Glenn Medalle,
Head of Talent -
Dr. Robert L. Nussbaum,
Chief Medical Officer -
Robert F. Werner,
Chief Accounting Officer & Principal Accounting Officer -
Desarie French,
Chief Talent Officer -
Laura D'Angelo,
Head of Investor Relations -
Yafei Wen,
Chief Financial Officer -
Layton Wedgeworth,
Chief Technology Officer -
Kenneth D. Knight,
Chief Operating Officer -
Michele Cargill Ph.D.,
Co-Founder, Key Projects & Advisor to the CEO -
Alex Furman,
Co-Founder, Culture Tsar & Head of People Analytics -
Bros. Advisors Lp Baker Bro...,
-
Bros. Advisors Lpbaker Feli...,
-
Mc Nerney & Partners Ii L.P...,
-
Lisa Alderson,
Senior VP, Marketing -
William H Osborne,
Director -
Patty Dumond,
-
Eric Thomas, Mc Nerney & Pa...,
-
James E Deerfield Mgmt L.P....,
-
E Lee Bendekgey,
Chief Operating Officer -
Randal W. Scott,
Director -
Yafei Wen,
Chief Financial Officer -
Robert M. Guigley,
Chief Commercial Officer -
David Sholehvar,
Chief Operating Officer -
Ana J. Schrank,
Chief Financial Officer